<DOC>
	<DOCNO>NCT00820352</DOCNO>
	<brief_summary>Heart failure major medical socioeconomic problem western industrial country , especially age population . Heart failure normal leave ventricle systolic function ( heart failure preserve ejection fraction , HFPEF , heart failure normal ejection fraction , HFNEF ) common cause hospitalization mainly elderly population frequently associate pulmonary hypertension . It commonly see , patient leave heart disease pulmonary hypertension right ventricle dysfunction bad prognosis . The investigator hypothesize , additional treatment Bosentan patient improve exercise capacity , symptom , hemodynamics quality life .</brief_summary>
	<brief_title>Safety Efficacy Bosentan Patients With Diastolic Heart Failure Secondary Pulmonary Hypertension</brief_title>
	<detailed_description>Heart Failure preserve ejection fraction 50 % case common form heart failure . Typically patient elderly woman arterial hypertension . Mortality , hospitalization rate due heart failure in-hospital complication differ significantly patient systolic heart failure . However subgroups HFPEF-patients bad prognosis , example 30 % patient develop secondary pulmonary hypertension thus right ventricle dysfunction . Increased right-ventricle systolic pressure associate increased mortality patient forms heart failure . There lack evidence HFPEF . Drugs treat systolic heart failure show improvement mortality prognosis . Diuretics able relieve symptom . There clinical trial concern HFPEF secondary pulmonary hypertension . The endothelin system activate PAH , also pulmonary venous hypertension congestive heart failure , ET-1 level rise severity secondary pulmonary hypertension . Pulmonary congestion lead endothelial dysfunction result increase level Endothelin-1 ( ET-1 ) . ET-1 potent vasoconstrictor . In pulmonary arterial vessel ETA receptor predominant receptor ( ratio ETA ET B = 9:1 ) , responsible vasoconstriction remodel pulmonal vasculature . In heart failure ETA receptor upregulated . Elevated plasma ET-1 level correlate pulmonary artery pressure ( PAP ) , pulmonary vascular resistance ( PVR ) inversely peak exercise capacity . Recent clinical laboratory finding indicate comparable pathophysiological mechanism pulmonary hypertension secondary leave ventricular dysfunction pulmonary arterial hypertension . Yet , despite expand application pulmonary artery hypertension , accord current opinion , oral dual endothelin ( ETA/ETB ) antagonist bosentan indicated PVH cause left ventricle / leave atrial pressure overload preserve systolic function . However , several study show effect pulmonary vessel dilate drug PAH leave ventricle dysfunction .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Clinically sign history congestive heart failure NYHA IIIII ( Fatigue , dyspnea exertion , lung crepitation , pulmonary edema , ankle low leg swelling , jugular pressure enhancement , hepatomegaly ) Echocardiographic sign diastolic dysfunction ( heart failure normal ejection fraction ) Right ventricle enlargement pulmonary hypertension 6 minute walk distance &gt; 150 &lt; 400 Right Heart Catheterization : Mean PAP &gt; 25 mmHg , PCWP &gt; 15 mmHg Echocardiographic requirement definition heart failure normal ejection fraction E/E ` &gt; 15 , E/E ` &gt; 8 + NTpBNP &gt; 220 pg/ml , E/E ` &gt; 8 + E : A &lt; 0.5 + DT &gt; 280 m ArdAd &gt; 30 m atrial enlargement atrial fibrillation NTpBNP &gt; 220 pg/ml + combination IVRT IVRTm &lt; 0 septal und lateral Echocardiographic requirement pulmonary hypertension right ventricle dysfunction RVEDD &gt; 30 mm short axis parasternal , one following : Tricuspid valve regurgitation velocity ( TRV ) &gt; 3 m/s ; RVannular systolic velocity &lt; 10 cm/sec ( TDI ) TAPSE &lt; 18 mm Patients guideline conform treatment cardiovascular disease . Left ventricle systolic dysfunction ( EF &lt; 50 % ) , aortic stenosis peak gradient ( instantane ) &gt; 40 mm Hg , moderate severe aortic insufficiency moderate severe mitral regurgitation , acute coronary disease , stable coronary artery disease peripheral vascular disease limit exercise . Other cause pulmonary artery hypertension : relevant obstructive ventilatory disease &gt; grade II ( lung function test ) collagen disease ( Tests : MSCT ANA , ANCA ) , chronic thrombo embolic pulmonary arterial hypertension ( MSCT ) , sleep disorder . HIV , HCV , HBV infection . Drug related PAH . Orthopaedic disease , immobility , inability perform 6MWT cancer . Liver disease ChildPugh B C , three fold normal elevate liver enzyme , anaemia Hb &lt; 10 mg/dl , specific treatment pulmonary arterial hypertension include endothelin receptor blocker , phosphodiesterase inhibitor , prostaglandin Larginin drug therapy glibenclamide , rifampicin , tacrolimus , sirolimus , cyclosporine A known adverse reaction bosentan pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HFNEF</keyword>
	<keyword>HFPEF</keyword>
	<keyword>Secondary Pulmonary Hypertension</keyword>
	<keyword>Endothelin Receptor Blockade</keyword>
</DOC>